DK3020729T3 - Antistoffer mod human il-22 og anvendelser deraf - Google Patents

Antistoffer mod human il-22 og anvendelser deraf Download PDF

Info

Publication number
DK3020729T3
DK3020729T3 DK15184078.2T DK15184078T DK3020729T3 DK 3020729 T3 DK3020729 T3 DK 3020729T3 DK 15184078 T DK15184078 T DK 15184078T DK 3020729 T3 DK3020729 T3 DK 3020729T3
Authority
DK
Denmark
Prior art keywords
applications
antibodies against
against human
human
antibodies
Prior art date
Application number
DK15184078.2T
Other languages
English (en)
Inventor
Jing Li
Ralph R Minter
Davinder S Gill
Geertruida M Veldman
Lynette A Fouser
Viia Valge-Archer
David C Lowe
Caroline S Russell
Suzanne E Cohen
Albert B Thom
Original Assignee
Wyeth Llc
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38236225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3020729(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc, Medimmune Ltd filed Critical Wyeth Llc
Application granted granted Critical
Publication of DK3020729T3 publication Critical patent/DK3020729T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK15184078.2T 2006-02-21 2007-02-21 Antistoffer mod human il-22 og anvendelser deraf DK3020729T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77459606P 2006-02-21 2006-02-21
EP11188458.1A EP2431392B1 (en) 2006-02-21 2007-02-21 Antibodies against human IL-22 and uses therefor

Publications (1)

Publication Number Publication Date
DK3020729T3 true DK3020729T3 (da) 2019-07-29

Family

ID=38236225

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15184078.2T DK3020729T3 (da) 2006-02-21 2007-02-21 Antistoffer mod human il-22 og anvendelser deraf
DK07751204.4T DK1991584T3 (da) 2006-02-21 2007-02-21 Antistoffer mod human IL-22 og anvendelser deraf

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07751204.4T DK1991584T3 (da) 2006-02-21 2007-02-21 Antistoffer mod human IL-22 og anvendelser deraf

Country Status (32)

Country Link
US (4) US7901684B2 (da)
EP (3) EP1991584B1 (da)
JP (1) JP5150516B2 (da)
KR (2) KR20080113214A (da)
CN (1) CN101426816B (da)
AR (1) AR059604A1 (da)
AT (1) ATE538137T1 (da)
AU (1) AU2007217751B2 (da)
BR (1) BRPI0708101B8 (da)
CA (1) CA2643226C (da)
CR (1) CR10237A (da)
DK (2) DK3020729T3 (da)
EC (1) ECSP088751A (da)
ES (2) ES2377463T3 (da)
HK (1) HK1120813A1 (da)
HN (1) HN2008001292A (da)
HU (1) HUE044595T2 (da)
IL (1) IL193605A (da)
MX (2) MX2008010708A (da)
MY (1) MY146664A (da)
NO (1) NO20083715L (da)
NZ (1) NZ570878A (da)
PE (1) PE20080111A1 (da)
PL (2) PL1991584T3 (da)
PT (2) PT1991584E (da)
RU (1) RU2467016C2 (da)
SA (1) SA07280062B1 (da)
SG (1) SG172628A1 (da)
SI (2) SI1991584T1 (da)
TW (1) TWI417301B (da)
WO (1) WO2007098170A1 (da)
ZA (1) ZA200807278B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2295026T3 (es) * 1999-04-28 2008-04-16 Genetics Institute, Llc Proteinas gil-19/ae289 humanas y polinucleotidos que codifican las mismas.
RU2426742C2 (ru) 2005-12-02 2011-08-20 Дженентек, Инк. Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
EP2337799A2 (en) * 2008-08-28 2011-06-29 Wyeth LLC Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
EP2419733A4 (en) 2009-04-13 2013-12-25 Univ Leland Stanford Junior METHODS AND DEVICES FOR DETECTING THE PRESENCE OF AN ANALYTE IN A SAMPLE
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
CN102652259B (zh) * 2010-03-12 2016-07-27 小利兰·斯坦福大学托管委员会 基于磁性传感器的定量结合动力学分析
WO2011139974A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
WO2014015133A1 (en) * 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
CA2878712A1 (en) * 2012-08-31 2014-03-06 arGEN-X BV Method for producing antibody molecules having inter-species, intra-target cross-reactivity
EP3385277A1 (en) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22 polypeptides and il-22 fc fusion proteins and methods of use
CN105139918B (zh) * 2015-06-26 2017-04-12 哈尔滨工业大学 一种柔板印刷用低银高性能导电浆料及其制备方法
CN105601739B (zh) * 2016-02-22 2019-01-18 王晨辉 一种人源化抗白介素22基因工程抗体及其应用
WO2018039107A1 (en) * 2016-08-22 2018-03-01 Medimmune, Llc Binding molecules specific for notch4 and uses thereof
CN110402393A (zh) * 2016-11-24 2019-11-01 休伯特保健公司 疾病诊断的组合物
CN117630386A (zh) 2016-11-28 2024-03-01 中外制药株式会社 包含抗原结合结构域和运送部分的多肽
KR102536314B1 (ko) * 2018-05-23 2023-05-25 주식회사 휴벳바이오 질환의 진단용 조성물
CN112292396A (zh) 2018-06-05 2021-01-29 生物蛋白有限公司 抗il-22抗体，抗体片段，其免疫结合物及其用途
EP3863602A1 (en) 2018-10-11 2021-08-18 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release
KR102226826B1 (ko) * 2020-08-06 2021-03-11 주식회사 휴벳바이오 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물
KR20230117588A (ko) 2020-12-07 2023-08-08 유씨비 바이오파마 에스알엘 다중특이적 항체 및 항체 조합
EP4255925A1 (en) 2020-12-07 2023-10-11 UCB Biopharma SRL Antibodies against interleukin-22
MX2023010238A (es) 2021-03-02 2023-12-05 Dana Farber Cancer Inst Inc Métodos para tratar trastornos de glóbulos rojos.
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
IL91501A (en) 1988-09-02 1998-03-10 Dyax Corp Generation of a variegated library of mutant potential binding proteins and screening of said library for proteins with a desired binding activity
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
ES2287206T3 (es) 1991-03-01 2007-12-16 Dyax Corporation Proceso para el desarrollo de mini-proteinas de union.
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
GB9214857D0 (en) 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
DE69330523T4 (de) 1992-08-21 2012-08-23 Vrije Universiteit Brussel Immunoglobuline ohne leichte ketten
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5674487A (en) * 1994-09-28 1997-10-07 Univ Jefferson Method for treating autoimmune diseases
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69621940T2 (de) 1995-08-18 2003-01-16 Morphosys Ag Protein-/(poly)peptidbibliotheken
DE122004000004I1 (de) 1996-02-09 2004-08-12 Abott Biotechnology Ltd Humane Antikörper welche an Humanen TNFalpha binden.
US20010006637A1 (en) * 1996-04-19 2001-07-05 Tohru Akahoshi Rheumatoid arthritis remedy containing anti-il-8 antibody as active ingredient
AU740043B2 (en) 1996-06-27 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
US6492507B1 (en) * 1996-10-23 2002-12-10 Incyte Genomics, Inc. Polynucleotides encoding human eosinophil-derived basic protein
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
US6551799B2 (en) * 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US20030032057A1 (en) * 1997-08-26 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002016611A2 (en) 2000-08-24 2002-02-28 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6350892B1 (en) 1997-09-23 2002-02-26 Bristol-Myers Squibb Company Trifluoromethyl ketone analogs as selective cPLA2 inhibitors
EP1049717B1 (en) * 1998-01-23 2007-03-21 F. Hoffmann-La Roche Ag Antibodies against human il-12
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
JP2002516103A (ja) 1998-05-29 2002-06-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド インターロイキン２１およびインターロイキン２２
AU760224B2 (en) * 1998-10-26 2003-05-08 Wyeth Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
US7081528B2 (en) * 1998-10-26 2006-07-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding T cell derived inducible factors
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
CN1202128C (zh) 1998-12-08 2005-05-18 拜奥威神有限公司 修饰蛋白的免疫原性
BR0009323A (pt) 1999-03-25 2002-01-08 Knoll Gmbh Anticorpos humanos que ligam a il-12 humana e métodos para a produção
US7307161B1 (en) * 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
CA2373231A1 (en) * 1999-05-19 2000-11-23 Incyte Genomics, Inc. Extracellular signaling molecules
AU5047600A (en) 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
ATE448246T1 (de) 1999-06-15 2009-11-15 Genentech Inc Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
WO2001040467A1 (en) * 1999-12-03 2001-06-07 Zymogenetics, Inc. Human cytokine receptor
US20030170823A1 (en) * 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
EP1242600B1 (en) 1999-12-23 2010-03-03 ZymoGenetics, Inc. Cytokine zcyto18
CN1400968A (zh) 2000-01-27 2003-03-05 美国氰胺公司 制备α－磺酰基异羟肟酸衍生物的方法
KR101111103B1 (ko) * 2000-02-10 2012-02-13 아보트 러보러터리즈 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법
AU7303301A (en) 2000-07-27 2002-02-13 Ludwig Inst Cancer Res Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
US20030012788A1 (en) * 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
US7094570B2 (en) * 2003-03-11 2006-08-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a soluble IL-TIF/IL-22 receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7638604B2 (en) * 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
NZ527396A (en) 2001-02-23 2007-12-21 Genetics Inst Llc Antibodies and fragments thereof for the binding of IL-22 and use therefore for treating inflammatory disorders
US20040058445A1 (en) 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US20020187512A1 (en) 2001-09-10 2002-12-12 Nagem Ronaldo Alves Pinto Crystal structure of human interleukin-22
IL164181A0 (en) 2002-03-22 2005-12-18 Zymogenetics Inc Anti-il-tif antibodies and methods of using in inflammation
US7375192B2 (en) * 2002-05-01 2008-05-20 Human Genome Sciences, Inc. Antibodies that specifically bind to chemokine beta-4
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
CN1839157A (zh) * 2003-06-23 2006-09-27 遗传研究所公司 抗白介素－22抗体及其应用
WO2007004788A1 (en) 2005-07-04 2007-01-11 Samsung Electronics Co., Ltd. Position measuring system and method using wireless broadband (wibro) signal
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
US8359965B2 (en) 2007-09-17 2013-01-29 Oxford J Craig Apparatus and method for broad spectrum radiation attenuation

Also Published As

Publication number Publication date
JP2009531023A (ja) 2009-09-03
BRPI0708101A2 (pt) 2011-05-17
ES2377463T3 (es) 2012-03-27
PL1991584T3 (pl) 2012-05-31
US20130005033A1 (en) 2013-01-03
EP1991584A1 (en) 2008-11-19
TW200801041A (en) 2008-01-01
NO20083715L (no) 2008-11-06
RU2008134137A (ru) 2010-03-27
US8182817B2 (en) 2012-05-22
KR20140100589A (ko) 2014-08-14
KR101616712B1 (ko) 2016-04-29
ATE538137T1 (de) 2012-01-15
JP5150516B2 (ja) 2013-02-20
US20070243589A1 (en) 2007-10-18
US20110275790A1 (en) 2011-11-10
EP2431392B1 (en) 2015-09-09
MY146664A (en) 2012-09-14
PL3020729T3 (pl) 2019-12-31
AR059604A1 (es) 2008-04-16
EP1991584B1 (en) 2011-12-21
CA2643226C (en) 2016-04-12
US8187603B2 (en) 2012-05-29
PT1991584E (pt) 2012-02-20
AU2007217751B2 (en) 2012-08-23
US8470993B2 (en) 2013-06-25
KR20080113214A (ko) 2008-12-29
EP3020729A1 (en) 2016-05-18
SG172628A1 (en) 2011-07-28
CA2643226A1 (en) 2007-08-30
CR10237A (es) 2008-11-26
CN101426816A (zh) 2009-05-06
BRPI0708101A8 (pt) 2019-01-22
BRPI0708101B8 (pt) 2021-05-25
WO2007098170A1 (en) 2007-08-30
ZA200807278B (en) 2009-05-27
BRPI0708101B1 (pt) 2020-01-14
SI3020729T1 (sl) 2019-10-30
EP2431392A1 (en) 2012-03-21
PT3020729T (pt) 2019-08-06
PE20080111A1 (es) 2008-02-20
SA07280062B1 (ar) 2012-03-13
RU2467016C2 (ru) 2012-11-20
HUE044595T2 (hu) 2019-11-28
US20100184960A1 (en) 2010-07-22
ECSP088751A (es) 2008-11-27
TWI417301B (zh) 2013-12-01
ES2738731T3 (es) 2020-01-24
CN101426816B (zh) 2012-12-12
US7901684B2 (en) 2011-03-08
MX337778B (es) 2016-03-18
IL193605A (en) 2015-07-30
HN2008001292A (es) 2012-02-13
NZ570878A (en) 2011-09-30
HK1120813A1 (en) 2009-04-09
IL193605A0 (en) 2011-08-01
EP3020729B1 (en) 2019-06-26
AU2007217751A1 (en) 2007-08-30
MX2008010708A (es) 2008-11-14
DK1991584T3 (da) 2012-04-02
SI1991584T1 (sl) 2012-05-31

Similar Documents

Publication Publication Date Title
DK3020729T3 (da) Antistoffer mod human il-22 og anvendelser deraf
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
DK2993187T3 (da) Antistoffer rettet mod her-3 og anvendelser deraf
DK2209806T3 (da) Anti-hepcidin-antistoffer og anvendelser deraf
DK1904104T3 (da) SP35-antistoffer og anvendelser heraf
DK1994055T3 (da) Anti-5t4-antistoffer og anvendelser deraf
DK2068887T3 (da) SP35-antistoffer og anvendelser heraf
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK1838733T3 (da) Antistoffer rettet mod angiopoietin-2 og anvendelser deraf
DK1866339T3 (da) GTR-bindende molekyler og anvendelser heraf
DK1894567T3 (da) Ledsagende farmaceutiske midler og anvendelse deraf
DK2147096T3 (da) Modificerede faktor-VII-polypeptider og anvendelser deraf
DK2222706T3 (da) Antibodies against human nkg2d and uses thereof
DK2012773T3 (da) Lægemidler og anvendelser deraf
BRPI0717367A2 (pt) Di-hidropirazolonas substituídas e sua aplicação.
DK1846445T3 (da) PYY-agonister og anvendelser deraf
DK2032606T3 (da) Antistoffer og immunkonjugater og anvendelser deraf
DK2061814T3 (da) Antistoffer og immunokonjugater og anvendelse deraf.
DK2907827T3 (da) Humaniserede anti-faktor D-antistoffer og anvendelser deraf
DK1737961T3 (da) Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf
DK2328931T3 (da) Selektive anti-hepcidin-25-antistoffer og anvendelser deraf
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2096167T3 (da) Aptamer mod midkin og anvendelse deraf
NO20054709L (no) Sammenfoyningssystem og anvendelse av dette
DK2079485T3 (da) Phenylpropionamidforbindelser og anvendelsen deraf